Atea Pharmaceuticals (AVIR) AI Stock Analysis

• Market Cap: $365.63M
• Dividend Yield: N/A
• Average Volume (3M): 509.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: N/A
• EPS Growth: 14.33%
• Country: US
• Employees: 56
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.53
• Shares Outstanding: 78,126,790
• 10 Day Avg. Volume: 391,204
• 30 Day Avg. Volume: 509,898
• PEG Ratio: -0.07
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.08
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -48.52
• Enterprise Value/Ebitda: -1.86
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.75
• Revenue Forecast (FY): $5.74M

• Rating: 58 Neutral
• Price Target: $4.50 ▼(-3.23% Downside)
• Action: Reiterated Date: 01/31/26
• Date: Action: Reiterated 01/31/26

The score is held back primarily by weak financial performance (no revenue, large losses, and ongoing cash burn). Offsetting factors include constructive technical momentum and a positive earnings call centered on Phase III execution progress and stated cash runway through 2027, while valuation remains constrained by negative earnings and no dividend.

Positive Factors

Cash runway / Liquidity

Having ~$329M in liquid resources that fund operations through 2027 materially reduces near-term financing pressure, allowing management to complete Phase III programs and generate pivotal data before needing large dilutive raises; that buffer supports strategic optionality.

Low leverage

Extremely low debt keeps fixed obligations minimal, preserving financial flexibility to fund R&D and pursue partnerships or licensing deals without interest strain; this structural balance-sheet strength lowers bankruptcy risk and supports long-term clinical execution.

Advanced HCV program and differentiation

On-track Phase III timelines, plus data showing a dual mechanism and no acid-reducer interactions, represent durable commercial differentiation versus incumbents and expand addressable use (e.g., patients on PPIs). Successful outcomes would convert the pipeline into a sustainable revenue engine.

Negative Factors

No recurring revenue and large losses

Atea remains a clinical-stage biotech with zero TTM revenue and large cumulative losses, meaning its long-term economics depend entirely on successful clinical outcomes or partner deals; until commercialization, profitability is unattainable and risk of dilution persists.

Sustained negative cash flow / burn

Persistent negative operating and free cash flow (~-$134M TTM) steadily depletes reserves; even with current runway, continued burn raises the probability of future equity raises or partnership dependence, which can dilute shareholders and constrain strategic choices.

Eroding equity base

A roughly 50% decline in book equity over recent years reflects cumulative operating losses and weak returns, reducing balance-sheet cushions that absorb trial setbacks, limiting borrowing capacity, and weakening negotiating leverage for co-development or licensing agreements.

Atea Pharmaceuticals Business Overview & Revenue Model

Company Description

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Atea Pharmaceuticals generates revenue through partnerships, collaborations, and potential future sales of its antiviral therapeutic products. The company has entered into significant partnerships, such as its collaboration with Roche, to fund development and commercialization of its product candidates. Revenue streams may include milestone payments, royalties, and licensing fees associated with these collaborations. Additionally, upon successful approval and commercialization of its drugs, Atea would earn revenue from direct sales of its antiviral therapies.

Atea Pharmaceuticals Financial Statement Overview

Summary

Weak operating profile with zero TTM revenue, large net losses (~-$147M), and materially negative operating/free cash flow (~-$134M). Offsetting positives include very low leverage (debt-to-equity ~0.003), but equity has declined meaningfully alongside continued losses.

Income Statement

TTM (Trailing-Twelve-Months) shows no revenue and significant losses (net income about -$147M), with deeply negative profitability. Annual results reflect a sharp shift from strong profitability in 2021 (revenue ~$351M, positive net income) to persistent losses from 2022–2024, with revenue falling to zero and losses remaining large. Strength: the company has previously demonstrated it can generate meaningful revenue/profits, but the current trajectory is clearly weak.

Balance Sheet

Leverage is very low (TTM debt-to-equity ~0.003), which reduces financial risk and provides flexibility. However, equity has declined meaningfully from 2021 to TTM (roughly $710M to ~$316M), consistent with ongoing losses and cash burn, and returns on equity are strongly negative in recent periods. Strength: minimal debt burden; weakness: shrinking equity base and continued negative returns.

Cash Flow

Cash generation is weak: TTM operating cash flow and free cash flow are both about -$134M, indicating continued cash burn to fund operations. While free cash flow improved versus the prior period (positive growth in TTM), cash flow has been consistently negative in most recent years (2021–TTM), which increases dependence on existing cash reserves or future financing. Strength: recent burn rate is slightly improving; weakness: still materially negative cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	351.37M	48.63M
Gross Profit	-5.96M	-83.37M	-70.09M	-62.39M	184.16M	10.61M
EBITDA	-155.22M	-131.80M	-119.59M	-110.84M	138.41M	-11.01M
Net Income	-147.03M	-168.38M	-135.96M	-115.91M	121.19M	-10.95M
Balance Sheet
Total Assets	342.96M	464.67M	594.97M	666.71M	772.89M	863.63M
Cash, Cash Equivalents and Short-Term Investments	329.31M	454.72M	578.11M	646.71M	764.38M	850.12M
Total Debt	1.04M	1.64M	2.40M	3.12M	197.00K	0.00
Total Liabilities	27.18M	25.80M	39.78M	26.14M	62.81M	315.83M
Stockholders Equity	315.78M	438.87M	555.19M	640.57M	710.08M	547.80M
Cash Flow
Free Cash Flow	-134.21M	-135.50M	-85.39M	-122.92M	-87.01M	296.71M
Operating Cash Flow	-134.21M	-135.50M	-85.39M	-120.98M	-87.00M	296.73M
Investing Cash Flow	138.83M	56.10M	40.30M	-455.41M	-4.00K	-26.00K
Financing Cash Flow	-25.75M	267.00K	257.00K	370.00K	1.47M	531.75M

Atea Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVIR, the sentiment is Positive. The current price of 4.65 is above the 20-day moving average (MA) of 4.35, above the 50-day MA of 3.85, and above the 200-day MA of 3.40, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 67.09 is Neutral, neither overbought nor oversold. The STOCH value of 74.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVIR.

Atea Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVIR	58 Neutral	$365.63M	-2.64	-37.98%	―	―	14.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OABI	50 Neutral	$247.60M	-2.91	-22.37%	―	3.36%	5.15%
HRTX	48 Neutral	$224.36M	-9.88	―	―	12.60%	58.23%
CDXS	42 Neutral	$91.23M	-1.34	-114.26%	―	-17.87%	14.42%
PRQR	42 Neutral	$167.50M	-3.48	-99.45%	―	-11.99%	-42.04%